Navigation Links
Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
Date:12/16/2010

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.  

"We are very encouraged by the progress made to date in our Factor VIIa program, the most advanced program within Catalyst's hemostasis franchise," said Nassim Usman, Ph.D., Catalyst's CEO.  "In addition to our work with Pfizer, Catalyst has independently achieved significant progress in engineering highly differentiated recombinant human Factor IX and Xa variants for acute and prophylactic treatment of bleeding disorders, including both hemophilia and non-hemophilia indications.  Catalyst expects to expand and strengthen this pipeline of novel engineered proteases in the coming year." 

In June 2009 Catalyst and Wyeth LLC (the successor to Wyeth), a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding, and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments.  

About Catalyst Biosciences  Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases.  Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
2. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
3. Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
4. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
5. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
6. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
7. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
8. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
9. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ... very important aspects in today,s growth in ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 /PRNewswire/ ... HTWR ), a leading innovator of less ... the treatment of advanced heart failure, today announced ... of 2013 will be approximately $53 million, bringing ... "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic ... LLC ("GMH"), announced today that it acquired Progressive Home Medical ... on January 7, 2014. The terms of the acquisition were ... durable medical equipment ("DME") company providing a wide range of ... Pennsylvania and Pittsburgh ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Bedford Laboratories™, a division of Ben Venue Laboratories, ... Topotecan Hydrochloride for Injection, 4 mg (base)/vial to ... the reference listed drug Hycamtin ® (topotecan ... Injection is indicated for the treatment of metastic ...
... Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2011 on Wednesday, April 27, 2011, after the close of ... will host a conference call to review the results beginning ... The press release and a live audio-only ...
Cached Medicine Technology:Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:4/14/2014)... moderate to severe obstructive sleep apnea is independently associated ... , Results of the 20-year follow-up study show that ... four times more likely to die (hazard ratio = ... stroke (HR = 3.7), three times more likely to ... more likely to develop cancer. Results were adjusted for ...
(Date:4/14/2014)... April 14, 2014 Popular web information on ... to read and doesn,t address the appropriate risks to ... Medical Center gastroenterologists suggests. , In a review of ... education materials for colorectal cancer screening were written beyond ... sites failed to address key risks, as well as ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... still more evidence that antibiotics can contribute to ... the journal Antimicrobial Agents and Chemotherapy ... weight and had significant changes in their gut ... Raoult, of Aix-Marseille University, Marseille, France, followed 48 ... and hydroxychloroquine for Q fever, and 34 control ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Long-term antibiotic treatment for Q fever causes weight gain 2Health News:Low birth weight, less breastfeeding create later health risks 2
... , THURSDAY, Dec. 23 (HealthDay News) -- Use of ... improving quality of care at U.S. hospitals, suggests a new ... rather the methods used to assess its effectiveness. Researchers ... for three common conditions -- heart failure, heart attack and ...
... By Jenifer Goodwin HealthDay Reporter , ... apixaban, may be better for preventing dangerous blood ... surgery than a commonly used older drug, a new ... anti-clotting drugs in a head-to-head test involving about 5,400 ...
... By Dennis Thompson HealthDay Reporter , THURSDAY, Dec. ... a disease of old age, with people,s joints growing creaky ... hundreds of thousands of kids in the United States. Children ... joints and impaired mobility if the disease isn,t caught in ...
... could lead to new treatments for patients with malignant ... discovered that a particular protein suppresses the progression of ... for cancer growth. The study is published in the ... studied the natural progression of melanoma using mouse and ...
... Eating a Southern staple, fried fish, could be one ... are more likely than other Americans to die of a ... 2010, online issue of Neurology, the medical journal of the ... belt states Alabama, Arkansas, Georgia, Louisiana, Mississippi, North Carolina, ...
... (HealthDay News) -- President Barack Obama is expected to ... gives the U.S. Food and Drug Administration unprecedented powers ... The Food Safety Modernization Act, passed by the House ... first significant strengthening of the nation,s food safety laws ...
Cached Medicine News:Health News:Electronic Health Records May Not Always Improve Care 2Health News:New Anti-Clotting Drug May Work Better After Hip Replacement 2Health News:New Anti-Clotting Drug May Work Better After Hip Replacement 3Health News:Doctor Shortage Adds to Pain of Juvenile Arthritis 2Health News:Doctor Shortage Adds to Pain of Juvenile Arthritis 3Health News:Doctor Shortage Adds to Pain of Juvenile Arthritis 4Health News:Mount Sinai researchers make major breakthrough in melanoma research 2Health News:America's stroke belt partially fueled by fried fish 2Health News:U.S. Food-Safety Laws Overhauled 2Health News:U.S. Food-Safety Laws Overhauled 3
... easy, breezy, beautiful image to its eyewear ... of stylish colors, trendy shapes, spring hinges, ... to target the broad demographics of the ... fashionable frames. The Cover Girl Eyewear collection ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... The license agreement between Brook Brothers ... 1993. Characterized by lightweight materials and ... collections reflect the unique features of ... A product with classic style and ...
... debuted in 1937 with the Aviator style ... to Luxottica Group's brand portfolio in 1999. ... celebrities since day one, Ray-Bans styles are ... best-selling sunglasses in the world. Characterized by ...
Medicine Products: